Equine ATG
Equine ATG Uses, Dosage, Side Effects, Food Interaction and all others data.
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types. Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic effect in these conditions.
There are currently various ATG products available, which differ in the source of inoculated animal (rabbit, horse, or pig) and in the type of antigen product used to produce immunoglobulin (thymocytes, peripheral T cells, etc.).
| Trade Name | Equine ATG |
| Generic | Antilymphocyte immunoglobulin (horse) |
| Antilymphocyte immunoglobulin (horse) Other Names | Anti-thymocyte Globulin (Equine), Anti-thymocyte globulin equine, eATG, equine ATG, Equine thymocyte immune globulin, hATG, Horse anti-thymocyte globulin, Horse ATG, Lymphocyte immune globulin anti-thymocyte globulin (equine), Lymphocyte immune globulin, anti-thymocyte globulin |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Equine ATG is a primarily IgG immune globulin used to manage allograft rejection in renal transplant patients.
For prevention of renal transplant rejection and for the treatment of aplastic anemia.
Equine ATG is also used to associated treatment for these conditions: Graft Versus Host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Lung Transplant Rejection, Moderate Aplastic Anemia, Myelodysplastic Syndrome, Severe Aplastic Anemia (SAA)
Toxicity
The most commonly reported adverse reactions (occurring in greater than 10% of patients) are pyrexia, chills, rash, thrombocytopenia, leukopenia and arthralgia.
Food Interaction
No interactions found.Volume of Distribution
During infusion of 10 to 15 mg/kg/day, the mean peak value (n = 27 renal transplant patients) was found to be 727 ± 310 μg/mL.
Half Life
The half-life of equine immunoglobulin after ATGAM infusion was found to be 5.7 ± 3.0 days in one group of recipients. The range for half-life was 1.5 to 13 days.
Innovators Monograph
You find simplified version here Equine ATG
